Fundraising Fox

A-Alpha Bio

Seattle, US · Founded 2017 · Delaware corporation · 7 known investors

aalphabio.com ↗

A-Alpha Bio uses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical discovery and development. The company operates experimental (AlphaSeq) and computational (AlphaBind) platforms to accelerate the design of novel therapeutics.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

A-Alpha Bio was founded in 2017 by David Younger, PhD, Randolph Lopez, PhD, David Younger, and Randolph Lopez.

DY
David Younger, PhDChief Executive Officer & Co-Founder
RL
Randolph Lopez, PhDChief Technology Officer & Co-Founder
DYDavid Younger
David YoungerinCo-Founder and CEO
RLRandolph Lopez
Randolph LopezinCo-founder & CTO

Investors · 7

Angel Collective Opportunity FundSan Francisco
Breakout VenturesSan Francisco · $500K – $6M
Farvatn VentureBergen
Lux CapitalNew York · $100K – $100M
Madrona Venture GroupSeattle · $2M – $10M
Boom Capital VenturesreportedSan Francisco · $50K – $300Kvia Celestine Schnugg · inferred
OS FundreportedPark Ridge · $1M – $2M

Reported raises · per SEC filings

Form D private placements

$23.1M disclosed across 2 rounds · 2019–2021

▶$20.3MraisedSep 2021 · 18 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ben AskewDirector
  • Randolph Lopez BarrezuetaDirector
  • Matt McIlwainDirector
  • David YoungerExecutive Officer, Director
Offering amount
$20.3M
Amount sold
$20.3M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedSep 2019 · 15 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • David YoungerExecutive Officer, Director, Promoter
Offering amount
$2.8M
Amount sold
$2.8M
First sale
Sep 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
AskBio12 shared keywordsAskBio develops gene therapies based on adeno-associated virus (AAV) technology, with a clinical pipeline targeting central nervous system, neuromuscular, metabolic, and cardiovascular disorders. Founded in 2001 and operating as a subsidiary of Bayer AG, the company runs research and in-house AAV manufacturing across the US and Europe.
Google Deepmind12 shared keywordsGoogle DeepMind is an AI research organization that develops frontier AI models and systems, including the Gemini family of models spanning text, image, video, music, audio, and robotics applications. Its work also supports scientific discovery and includes open models and tools for building AI-powered products.

Companies competing with A-Alpha Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase II2020$620.5K
National Science FoundationPhase I2020$256K
National Science FoundationPhase I2018$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Sell or Invest in A-Alpha Bio Stock Pre-IPOnasdaqprivatemarket.com · Jun 2025A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development - Xontogenyxontogeny.com · Jul 2023A-Alpha Bio, a biotech startup that measures and predicts protein interactions, raises $22.4M – GeekWiregeekwire.com · Jul 2023A-Alpha Bio Raises $2.8 million in Seed Financing to Develop NGS-Based Protein Interaction Tech | GenomeWebgenomeweb.com · Sep 2019

Frequently asked questions

What does A-Alpha Bio do?
A-Alpha Bio uses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical discovery and development. The company operates experimental (AlphaSeq) and computational (AlphaBind) platforms to accelerate the design of novel therapeutics.
Who founded A-Alpha Bio?
A-Alpha Bio was founded by David Younger, PhD, Randolph Lopez, PhD, David Younger, Randolph Lopez in 2017.
Who are A-Alpha Bio's investors?
A-Alpha Bio's investors include Angel Collective Opportunity Fund, Breakout Ventures, Farvatn Venture, Lux Capital, Madrona Venture Group, Boom Capital Ventures, OS Fund.
How much funding has A-Alpha Bio raised?
A-Alpha Bio has disclosed $23.1M raised across 2 rounds.
Where is A-Alpha Bio headquartered?
A-Alpha Bio is headquartered in Seattle, US.